Five Prime Therapeutics Inc (FPRX) 24.63 $FPRX
Five Prime Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 3:06PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:25 AM Eastern Standard Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
FPRX: 24.63 (+0.63)
5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Feb 04, 10:59AM CST
Bristol-Myers Squibb 's dramatic reorganization effort, following the loss of patent protection for several top-selling drugs, appears to be hitting an inflection point. Although total revenue was down by 3% in 2014, to $15.9 billion, the...
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), FPRX: 24.63 (+0.63), CELG: 115.88 (+0.16)
Insider Buys And Sells: A. M. Castle, Microsoft
Asif Suria - at Seeking Alpha - Sun Feb 01, 10:57AM CST
Welcome to edition 241 of Insider Weekends. Insider buying increased significantly last week with insiders buying $196.76 million of stock compared to $16.43 million in the week prior. Selling also increased with insiders selling $1.49 billion of...
RF: 9.52 (-0.02), EA: 56.39 (+0.20), LGF: 32.17 (+0.08), CAS: 6.14 (-0.01), TWTR: 48.50 (+0.55), MSFT: 43.87 (+0.78), TCBI: 48.51 (+0.81), SCHW: 29.13 (-0.83), FPRX: 24.63 (+0.63)
InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST
STX: 61.83 (+0.67), CSWC: 46.54 (+1.20), FCS: 16.37 (-0.07), MLNK: 3.78 (+0.04), ADBE: 76.51 (+1.92), VSAR: 18.04 (-0.55), LCI: 57.78 (-0.91), WIW: 11.29 (unch), QRVO: 70.03 (+3.83), PSEM: 14.82 (-0.12), OPK: 13.80 (-0.28), CUDA: 35.68 (-1.14), BGG: 20.18 (+0.09), RWC: 5.82 (+0.06), PE: 17.28 (+0.80), MSFT: 43.87 (+0.78), BK: 39.20 (-0.21), FPRX: 24.63 (+0.63), INFN: 17.56 (-0.10)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:50PM CST
Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense value in other unusual situations like mass disasters, missing persons, and unidentified human remains.
NLNK: 38.84 (+1.51), ALXN: 182.29 (+6.02), ILMN: 198.54 (+1.81), FPRX: 24.63 (+0.63)
5 Stocks Insiders Love Right Now: eHealth, Worthington Industries and More
at The Street - Wed Jan 21, 6:00AM CST
Insiders at these comapnies have been snapping up shares of their own stocks lately.
OVAS: 44.32 (+0.87), CDNA: 6.30 (-0.14), WOR: 31.13 (+0.33), FPRX: 24.63 (+0.63), EHTH: 10.91 (-0.04)
Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for Some Cancer Patie
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 18, 8:12AM CST
Source: Flickr user Eric Norris Cancer of any type is a terrifying disease to fight. There are simply so many unknowns associated with cancer, such as why it occurs in one person and not the next and what triggers its growth in the first place. ...
MRK: 58.81 (-0.07), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56), FPRX: 24.63 (+0.63)
InsiderInsights.com Daily Round Up 1/16/15: WOR, EHTH, OPK, FPRX
InsiderInsights - at Seeking Alpha - Sun Jan 18, 4:49AM CST
AFAM: 30.88 (+0.37), DEI: 29.24 (-0.20), GIII: 103.56 (+0.65), WOR: 31.13 (+0.33), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), GOOG: 549.01 (+6.08), K: 63.20 (-0.10), JPM: 59.67 (+0.10), SPW: 87.37 (-2.81), OPK: 13.80 (-0.28), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), DYN: 28.39 (+0.01), HBI: 119.12 (+1.27), PAYC: 32.37 (-0.71), EHTH: 10.91 (-0.04), FPRX: 24.63 (+0.63)
Five Prime Therapeutics Announces Closing of Public Offering
GlobeNewswire - Mon Jan 12, 9:00AM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the closing of its public offering of 3,829,944 shares of its common stock, which includes 419,994 shares sold upon the partial exercise of the underwriters' option to purchase additional shares, resulting in aggregate gross proceeds of $84.3 million, before underwriting discounts and commissions, structuring fees and expenses.
WFC: 55.33 (+0.47), FPRX: 24.63 (+0.63)
Bristol-Myers stops cancer trial early after Opdivo meets efficacy endpoint
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:29PM CST
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16), FPRX: 24.63 (+0.63)
Five Prime Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 3:06PM CST
Five Prime Therapeutics, Inc. (Nasdaq: FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 9:30 AM Pacific Standard Time. The conference will take place at the Westin St. Francis Hotel in San Francisco.
JPM: 59.67 (+0.10), FPRX: 24.63 (+0.63)
Today's Weak On High Volume Stock: Five Prime Therapeutics (FPRX)
at The Street - Wed Jan 07, 9:07AM CST
Trade-Ideas LLC identified Five Prime Therapeutics (FPRX) as a weak on high relative volume candidate
FPRX: 24.63 (+0.63)
Five Prime prices stock offering
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 7:22PM CST
FPRX: 24.63 (+0.63)
Five Prime Therapeutics Prices Public Offering of Common Stock
GlobeNewswire - Tue Jan 06, 7:10PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the pricing of an underwritten public offering of 3,410,000 shares of its common stock at a price of $22.00 per share for an aggregate offering of $75.0 million, before underwriting discounts and commissions, structuring fees and estimated expenses. All of the shares of common stock are being offered by Five Prime. In addition, Five Prime has granted the underwriters a 30-day option to purchase up to 511,500 additional shares of common stock at the offering price. The offering is expected to close on January 12, 2015, subject to customary closing conditions.
WFC: 55.33 (+0.47), FPRX: 24.63 (+0.63)
Five Prime to execute secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 3:39PM CST
FPRX: 24.63 (+0.63)
Five Prime Announces $75 Million Proposed Public Offering of Common Stock
GlobeNewswire - Mon Jan 05, 3:01PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced today that it plans to offer up to $75,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, Five Prime intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
FPRX: 24.63 (+0.63)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), MDCO: 29.79 (+0.91), BMY: 60.04 (+0.56), FPRX: 24.63 (+0.63)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 90.70 (+0.93), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), FPRX: 24.63 (+0.63), EXEL: 2.48 (+0.20)
Five Prime Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 3:06PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:25 AM Eastern Standard Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
FPRX: 24.63 (+0.63)
5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Feb 04, 10:59AM CST
Bristol-Myers Squibb 's dramatic reorganization effort, following the loss of patent protection for several top-selling drugs, appears to be hitting an inflection point. Although total revenue was down by 3% in 2014, to $15.9 billion, the...
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), FPRX: 24.63 (+0.63), CELG: 115.88 (+0.16)
Insider Buys And Sells: A. M. Castle, Microsoft
Asif Suria - at Seeking Alpha - Sun Feb 01, 10:57AM CST
Welcome to edition 241 of Insider Weekends. Insider buying increased significantly last week with insiders buying $196.76 million of stock compared to $16.43 million in the week prior. Selling also increased with insiders selling $1.49 billion of...
RF: 9.52 (-0.02), EA: 56.39 (+0.20), LGF: 32.17 (+0.08), CAS: 6.14 (-0.01), TWTR: 48.50 (+0.55), MSFT: 43.87 (+0.78), TCBI: 48.51 (+0.81), SCHW: 29.13 (-0.83), FPRX: 24.63 (+0.63)
InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST
STX: 61.83 (+0.67), CSWC: 46.54 (+1.20), FCS: 16.37 (-0.07), MLNK: 3.78 (+0.04), ADBE: 76.51 (+1.92), VSAR: 18.04 (-0.55), LCI: 57.78 (-0.91), WIW: 11.29 (unch), QRVO: 70.03 (+3.83), PSEM: 14.82 (-0.12), OPK: 13.80 (-0.28), CUDA: 35.68 (-1.14), BGG: 20.18 (+0.09), RWC: 5.82 (+0.06), PE: 17.28 (+0.80), MSFT: 43.87 (+0.78), BK: 39.20 (-0.21), FPRX: 24.63 (+0.63), INFN: 17.56 (-0.10)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:50PM CST
Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense value in other unusual situations like mass disasters, missing persons, and unidentified human remains.
NLNK: 38.84 (+1.51), ALXN: 182.29 (+6.02), ILMN: 198.54 (+1.81), FPRX: 24.63 (+0.63)
5 Stocks Insiders Love Right Now: eHealth, Worthington Industries and More
at The Street - Wed Jan 21, 6:00AM CST
Insiders at these comapnies have been snapping up shares of their own stocks lately.
OVAS: 44.32 (+0.87), CDNA: 6.30 (-0.14), WOR: 31.13 (+0.33), FPRX: 24.63 (+0.63), EHTH: 10.91 (-0.04)
Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for Some Cancer Patie
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 18, 8:12AM CST
Source: Flickr user Eric Norris Cancer of any type is a terrifying disease to fight. There are simply so many unknowns associated with cancer, such as why it occurs in one person and not the next and what triggers its growth in the first place. ...
MRK: 58.81 (-0.07), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56), FPRX: 24.63 (+0.63)
InsiderInsights.com Daily Round Up 1/16/15: WOR, EHTH, OPK, FPRX
InsiderInsights - at Seeking Alpha - Sun Jan 18, 4:49AM CST
AFAM: 30.88 (+0.37), DEI: 29.24 (-0.20), GIII: 103.56 (+0.65), WOR: 31.13 (+0.33), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), GOOG: 549.01 (+6.08), K: 63.20 (-0.10), JPM: 59.67 (+0.10), SPW: 87.37 (-2.81), OPK: 13.80 (-0.28), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), DYN: 28.39 (+0.01), HBI: 119.12 (+1.27), PAYC: 32.37 (-0.71), EHTH: 10.91 (-0.04), FPRX: 24.63 (+0.63)
Five Prime Therapeutics Announces Closing of Public Offering
GlobeNewswire - Mon Jan 12, 9:00AM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the closing of its public offering of 3,829,944 shares of its common stock, which includes 419,994 shares sold upon the partial exercise of the underwriters' option to purchase additional shares, resulting in aggregate gross proceeds of $84.3 million, before underwriting discounts and commissions, structuring fees and expenses.
WFC: 55.33 (+0.47), FPRX: 24.63 (+0.63)
Bristol-Myers stops cancer trial early after Opdivo meets efficacy endpoint
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:29PM CST
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16), FPRX: 24.63 (+0.63)
Five Prime Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 3:06PM CST
Five Prime Therapeutics, Inc. (Nasdaq: FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 9:30 AM Pacific Standard Time. The conference will take place at the Westin St. Francis Hotel in San Francisco.
JPM: 59.67 (+0.10), FPRX: 24.63 (+0.63)
Today's Weak On High Volume Stock: Five Prime Therapeutics (FPRX)
at The Street - Wed Jan 07, 9:07AM CST
Trade-Ideas LLC identified Five Prime Therapeutics (FPRX) as a weak on high relative volume candidate
FPRX: 24.63 (+0.63)
Five Prime prices stock offering
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 7:22PM CST
FPRX: 24.63 (+0.63)
Five Prime Therapeutics Prices Public Offering of Common Stock
GlobeNewswire - Tue Jan 06, 7:10PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the pricing of an underwritten public offering of 3,410,000 shares of its common stock at a price of $22.00 per share for an aggregate offering of $75.0 million, before underwriting discounts and commissions, structuring fees and estimated expenses. All of the shares of common stock are being offered by Five Prime. In addition, Five Prime has granted the underwriters a 30-day option to purchase up to 511,500 additional shares of common stock at the offering price. The offering is expected to close on January 12, 2015, subject to customary closing conditions.
WFC: 55.33 (+0.47), FPRX: 24.63 (+0.63)
Five Prime to execute secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 3:39PM CST
FPRX: 24.63 (+0.63)
Five Prime Announces $75 Million Proposed Public Offering of Common Stock
GlobeNewswire - Mon Jan 05, 3:01PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced today that it plans to offer up to $75,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, Five Prime intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
FPRX: 24.63 (+0.63)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), MDCO: 29.79 (+0.91), BMY: 60.04 (+0.56), FPRX: 24.63 (+0.63)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 90.70 (+0.93), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), FPRX: 24.63 (+0.63), EXEL: 2.48 (+0.20)
